drugset / Trial / NCT04640545

A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma

NCT04640545

Phase 1 Completed 79 enrolled Nanjing Leads Biolabs Co.,Ltd
NaSingle-groupOpen-labelTreatment

Summary

A phase I clinical study evaluating LBL-007 in the treatment of subjects with advanced solid tumors

Timeline

Start
2020-05-12
Primary completion
2024-08-19
Completion
2024-08-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Alcestobart Monoclonal antibody Intravenous
Subject Axitinib Small molecule
Subject Toripalimab Monoclonal antibody Intravenous

Indications